The Medicines Co. (MDCO: Quote) reported results from its Phase 3 trial of its intravenous antiplatelet cangrelor to oral clopidogrel in patients undergoing percutaneous coronary intervention on Sunday. Patients treated with cangrelor had a 22% reduced odds of experiencing the primary endpoint, which was a composite incidence of death, myocardial infarction, ischemia-driven revascularization or stent thrombosis at 48 hours after randomization.
The Medicines Co. gapped open higher Monday and is now up 1.30 at $33.00. The stock has risen above a 2 1/2 week range and has set a new high for the year.
Click here to receive FREE breaking news email alerts for MEDICINES CO (THE) and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News